The molecule, DPT0218, was detected during preclinical animal trials.
DP Technology today announced the nomination of DPT0218, a novel small molecule targeting the potassium voltage-gated channel Kv1.3, as a preclinical candidate compound for the treatment of autoimmune diseases including atopic dermatitis (AD) and inflammatory bowel disease (IBD).1
The potassium channel Kv1.3 (also known as KCNA3) plays an essential role in T-cell proliferation and activation as well as cytokine production,2 and is crucial for maintaining the membrane potential required for the induction of inflammatory responses, according to DP Technology.
The molecule DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor, with “best-in-class" potential and a novel scaffold, according to the company. It has shown positive results in preclinical animal models of various autoimmune diseases such as IBD and AD, it reported, and has an excellent safety profile.
"Although antibodies play a pivotal role in the treatment of moderate to severe IBD, their applications are limited by constrained therapeutic efficacy, immunogenicity, parenteral route of drug delivery, poor tolerability, and high cost." said Xiaomin Zhang, head of drug discovery at DP Technology, in a company press release.
"As a small molecule, DPT0218 has shown potent inhibition of T-cell activation, proliferation, and cytokine secretion in both in vivo and in vitro studies, demonstrating its potential as an effective treatment for IBD. We'll actively advance DPT0218 to clinical research and explore its application to other autoimmune diseases."
References
1. DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD. DP Technology. News release. January 30, 2924. Accessed January 30, 2024.https://www.prnewswire.com/news-releases/dp-technology-announces-nomination-of-development-candidate-a-potential-best-in-class-kv1-3-inhibitor-for-immunological-diseases-including-ibd-and-ad-302047637.html
2. National Center for Biotechnology Information. KCNA3 potassium voltage-gated channel subfamily A member 3 [Homo sapiens (human)]. National Library of Medicine. Updated November 23. 2023. Accessed January 30, 2024.https://www.ncbi.nlm.nih.gov/gene/3738
This article was originally posted in Dermatology Times.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More